logo
  

Roche Gets Positive CHMP Opinion For Tecentriq/Avastin For Common Form Of Liver Cancer Treatment

Roche (RHHBY) said Friday that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP has recommended the approval of Tecentriq in combination with Avastin for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma or HCC who have not received prior systemic therapy.

A final decision regarding approval of Tecentriq in combination with Avastin in the disease setting is expected from the European Commission in the near future.

In May 2020, the US Food and Drug Administration approved Tecentriq in combination with Avastin for the treatment of people with unresectable or metastatic HCC who have not received prior systemic therapy.

In September 2020, the China National Medical Products Administration approved the combination for the treatment of people with unresectable HCC who have not received prior systemic therapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
PepsiCo, Inc. (PEP) has reached an agreement with private equity firm PAI Partners to sell Tropicana, Naked and other select juice brands across North America. The agreement also includes an irrevocable option to sell certain juice businesses in Europe. The combined pre-tax cash proceeds will be approximately... Drug major Eli Lilly And Co. reported Tuesday weak profit in its second quarter, despite higher revenues driven by strong volume across core business and most major geographies. Further, the company trimmed its forecast for fiscal 2021 earnings on a reported basis and margin, while maintained adjusted earnings view above market estimates. The company also tightened full-year revenue forecast. Shares of BMW Group were losing around 5 percent in German trading after the luxury automaker warned Tuesday that its second half-year is likely to be more volatile, affected by supply bottlenecks, high prices for raw materials and a shortage of semiconductors. This was despite reporting strong second-quarter results driven by solid demand.
Follow RTT